Adenovirus technology and bioprocessing publications
Ramachandra M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D, Sugarman
B, Demers GW, Engler H, Johnson D, Shabram P. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol. 2001 Nov;19(11):1035-41.
Huyghe BG, Liu X, Sutjipto S, Sugarman BJ, Horn MT, Shepard HM, Scandella CJ,
Shabram P. ,Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther. 1995 Nov;6(11):1403-16.
Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, Huyghe BG, Liu X,
Nunnally MH, Sugarman BJ, Sutjipto S. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther. 1997 Mar 1;8(4):453-65.
Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination.
Lloyd Snyder, (with Carl Scandella, Paul Shabram and Gary Vellekamp) Separation of Large Molecules, Section 6.2.2.4. Separation of Viruses. Submitted March 2006.
Lehmberg, E., Shabram, P., Schluep, T., Wen, Shu-Fen, Sugarman, B., Croyle, M., Koehl, M., Bonfils, E., Malarme, D., Sharpe, G., Nesbit, H.,Borellini, F., Hutchins, B., Vellekamp, G. Adenovirus Reference Material: Determination of Particle Concentrations Obtained by Orthogonal, Physical-Chemical Methods. BioProcessing Journal 2004, May-June, pp50-55
Shabram, P., Vellekamp. G., Scandella, C., Purification of Adenovirus in: Adenoviral Vectors for Gene Therapy edited by Curiel and Douglas, Academic Press, San Diego, CA 2002
Shabram P, Aguilar-Cordova E. Multiplicity of infection/multiplicity of confusion. Mol Ther. 2000 Nov;2(5):420-1.
Pierce L., Shabram P., Scaleability of a Disposable Bioreactor from 25L-500L Run in Perfusion Mode with a CHO-Based Cell Line: A Tech Review. BioProcessing Journal 2004, July-August, pp51-56
Patents
U.S. Patent No. 4,608,791, Computer controlled packaging machine.
U.S. Patent No. 5,837,520, Method of Purification of Viral Vectors. Preparative and analytical chromatography of viral vectors for gene therapy.
U.S. Patent No. 5,994,134, Viral Production Process. Bioreactor Process.
U.S. Patent No. 6,165,779, Composition and Methods for Therapeutic Use. Viral vectors formulated in delivery enhancing agent such as detergents or ethanol.
U.S. Patent No. Methods and Composition for Reducing Immune Response
Go to Top
Other publications
Aida I Saacan, Wilson R Edwards, Derrick Domingo, Jacqueline M Glynn, Stephen Hawley, Leigh Pierce, Paul Shabram, Donna Palmer Transport of Aerosolized IL-2 Chimeric Protein Using Polymeric Immunoglobulin Receptor in the LungRespiratory Drug Delivery IX, Vol 2, (2004): pp 357-360
Demers GW, Johnson DE, Tsai V, Wen SF, Quijano E, Machemer T, Philopena J,
Ramachandra M, Howe JA, Shabram P, Ralston R, Engler H.
Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy.
Cancer Res. 2003 Jul 15;63(14):4003-8.
Ramachandra M, Atencio I, Rahman A, Vaillancourt M, Zou A, Avanzini J, Wills K, Bookstein R, Shabram P. Restoration of transforming growth factor Beta signaling by functional expression of smad4 induces anoikis.and Cancer Res. 2002 Nov 1;62(21):6045-51.
Rahman A, Tsai V, Goudreau A, Shinoda JY, Wen SF, Ramachandra M, Ralston R,
Maneval D, LaFace D, Shabram P. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy. Mol Ther. 2001 May;3(5 Pt 1):768-78.
Atencio IA, Ramachandra M, Shabram P, Demers GW. Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. Cell Growth Differ. 2000 May;11(5):247-53.
Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW,
Wills KN, Shabram PW, Bolen JB, Tavtigian SV, Bookstein R. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res. 1998 Jun 1;58(11):2331-4.
Go to Top
|
